Robert F Kelley

Robert F Kelley

UNVERIFIED PROFILE

Are you Robert F Kelley?   Register this Author

Register author
Robert F Kelley

Robert F Kelley

Publications by authors named "Robert F Kelley"

Are you Robert F Kelley?   Register this Author

43Publications

1451Reads

20Profile Views

Tailoring translational strength using Kozak sequence variants improves bispecific antibody assembly and reduces product-related impurities in CHO cells.

Biotechnol Bioeng 2020 Apr 4. Epub 2020 Apr 4.

Departments of Cell Culture, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bit.27347DOI Listing
April 2020

Protein conjugates and fusion proteins as ocular therapeutics.

Drug Discov Today 2019 08 13;24(8):1440-1445. Epub 2019 Jun 13.

Drug Delivery Department, Genentech, Inc, South San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13596446183038
Publisher Site
http://dx.doi.org/10.1016/j.drudis.2019.05.025DOI Listing
August 2019

In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches.

Mol Pharm 2019 01 3;16(1):86-95. Epub 2018 Dec 3.

Department of Protein Chemistry , Genentech, Inc. , South San Francisco , California 94080 , United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.8b00871DOI Listing
January 2019

Strategies for modifying drug residence time and ocular bioavailability to decrease treatment frequency for back of the eye diseases.

Expert Opin Drug Deliv 2019 01 7;16(1):43-57. Epub 2018 Dec 7.

b School of Pharmaceutical Sciences , University of Geneva & University of Lausanne , Geneva , Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425247.2019.1553953DOI Listing
January 2019

Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.

MAbs 2017 07 2;9(5):756-766. Epub 2017 May 2.

c Department of Drug Delivery , Genentech Inc. , South San Francisco , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2017.1323160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524161PMC
July 2017

Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab.

Mol Pharm 2016 09 14;13(9):2996-3003. Epub 2016 Jun 14.

Departments of Protein Chemistry, ‡Antibody Engineering, §Early Stage Cell Culture, ∥Bioanalytical Assay Services, ⊥Preclinical and Translational Pharmacokinetics, and #Drug Delivery, Genentech Inc. , 1 DNA Way, South San Francisco, California 94080, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.6b00345DOI Listing
September 2016

Solubility Challenges in High Concentration Monoclonal Antibody Formulations: Relationship with Amino Acid Sequence and Intermolecular Interactions.

Mol Pharm 2015 Nov 6;12(11):3896-907. Epub 2015 Oct 6.

Summer Intern from Department of Pharmaceutical Sciences, University of Connecticut , Storrs, Connecticut 06269, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.molpharmaceut.5b00336DOI Listing
November 2015

Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab.

J Mol Biol 2013 Apr 25;425(8):1330-9. Epub 2013 Jan 25.

Department of Structural Biology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmb.2013.01.024DOI Listing
April 2013

Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function.

Methods Mol Biol 2012 ;901:277-93

Antibody Engineering, Genentech Inc, South San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-61779-931-0_18
Publisher Site
http://dx.doi.org/10.1007/978-1-61779-931-0_18DOI Listing
October 2012

Using linkage-specific monoclonal antibodies to analyze cellular ubiquitylation.

Methods Mol Biol 2012 ;832:185-96

Physiological Chemistry Department, Genentech, Inc., South San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-61779-474-2_13DOI Listing
July 2012

Engineering and structural characterization of a linear polyubiquitin-specific antibody.

J Mol Biol 2012 May 29;418(3-4):134-44. Epub 2011 Dec 29.

Department of Antibody Engineering, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmb.2011.12.053DOI Listing
May 2012

High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity.

PLoS One 2011 Apr 22;6(4):e17887. Epub 2011 Apr 22.

Department of Antibody Engineering, Genentech Inc., South San Francisco, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0017887PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081289PMC
April 2011

K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody.

Mol Cell 2010 Aug 22;39(3):477-84. Epub 2010 Jul 22.

Department of Antibody Engineering, Genentech, Inc., South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2010.07.001DOI Listing
August 2010

Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code.

J Mol Biol 2006 Mar 19;357(1):100-14. Epub 2005 Dec 19.

Department of Protein Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmb.2005.11.092DOI Listing
March 2006

Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding.

J Biol Chem 2005 Feb 12;280(8):7218-27. Epub 2004 Nov 12.

Department of Protein Engineering, Molecular Oncology, Medicinal Chemistry, and Immunology, Genentech, Inc., South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M411714200DOI Listing
February 2005

Engineering an APRIL-specific B cell maturation antigen.

J Biol Chem 2004 Apr 4;279(16):16727-35. Epub 2004 Feb 4.

Department of Protein Engineering, Genentech, Inc., South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M312316200DOI Listing
April 2004

Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity.

Biochemistry 2004 Feb;43(5):1223-9

Departments of Protein Engineering and Physiology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi035738iDOI Listing
February 2004

BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site.

Biochemistry 2003 May;42(20):5977-83

Department of Protein Engineering, Genentech, Inc., One DNA Way, South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi034017gDOI Listing
May 2003

Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa.

Thromb Haemost 2002 Mar;87(3):450-8

Department of Protein Engineering, Genentech, Inc., South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
March 2002